Arie Belldegrun Buys 20,000 Shares of URGN
On June 22, Arie Belldegrun purchased 20,000 shares of URGN.
Key Points
- Arie Belldegrun bought 20,000 shares of URGN on June 22, 2026, with shares trading near $35.8.
- URGN's stock saw activity from several institutional investors, including BlackRock, Inc. and Toronto Dominion Bank.
- Analysts like HC Wainwright & Co. and Oppenheimer maintain buy ratings on URGN with targets up to $45.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Arie Belldegrun, a noted insider, purchased 20,000 shares of URGN on June 22, 2026. The transaction was not planned in advance and occurred as the company's shares traded near $35.8.
Other Institutional Activity in URGN
Institutional investors have also been active in URGN's stock. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at approximately $51.2 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth about $47 million. Meanwhile, Morgan Stanley slightly reduced its stake by 2,863 shares, ending with 2,560,038 shares valued at $46 million. Kynam Capital Management, LP also initiated a new position, holding 2,247,393 shares valued at around $40.4 million.
UroGen Pharma Ltd. Stock Down 18.4%
As of Wednesday, URGN shares were trading near $35.8. The company has seen various institutional movements, reflecting interest in its potential. Analysts have maintained positive ratings, suggesting confidence in its future performance.
$URGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders, including Robinson James Jr., Leana Wen, and Cynthia Butitta, also bought shares of URGN. Robinson James Jr. acquired a total of 18,000 shares, while Leana Wen and Cynthia Butitta each bought 10,000 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
Analysts continue to show optimism for URGN. On May 11, 2026, HC Wainwright & Co. maintained a buy rating with a $45 price target. Oppenheimer also upheld its buy rating with a $40 target on May 7, 2026. Overall, the consensus remains positive, with a strong buy recommendation and an average target price reflecting potential growth.
Bottom Line
Arie Belldegrun's recent purchase of URGN shares highlights insider confidence in the company's prospects. Institutional activity further underscores this interest, with both new positions and increased holdings reported. Analysts echo this sentiment with maintained buy ratings and robust price targets, suggesting continued optimism in URGN's future performance.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.